Quick Links

Local or global—RAPS has you covered with offices in Washington, DC, Shanghai and Singapore. There are RAPS chapters in Canada, Israel, Switzerland, Taiwan and throughout the United States, and local networks in Australia, Belgium, Brazil, Germany, India, Mexico, The Netherlands, Poland and Singapore.

Quick Links

It’s well-known that the National Institutes of Health (NIH) offers billions of dollars in grants to US academic research facilities. What’s less well-known is that each year, hundreds of new inventions are produced in the laboratories of NIH, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), and these inventions are licensed out to private companies in the US and internationally for further research and development, with the hopes of bringing new products to market.

RAPS’ members-only online community, Regulatory Exchange or “RegEx” as it is often called, was recently named one of three “Most Successful Community” award winners of 2016 by Higher Logic. RegEx is built on the Higher Logic platform.

Biologics manufacturer Peregrine Pharmaceuticals' has informed its investors that its second-line lung cancer drug bavituximab, for which the company just released phase IIb data showing evidence of efficacy, is plagued by faulty data it says is the result of poor work by a third-party clinical trials contractor.

In its 24 September release, Peregrine said it discovered the deficient data when preparing for an end-of-phase II meeting with the US Food and Drug Administration (FDA). The company, it said, "Discovered major discrepancies between some patient sample test results and patient treatment code assignments."

The study, started in June 2012, was a placebo-controlled study comparing a control group with two treatments groups receiving Docataxel plus either bavituximab 1mg/kg or 3mg/kg. The trial was being conducted at 53 study locations throughout the US, India, Russia and the Ukraine. At the time of the study's release, the company's chief of regulatory affairs, Robert Garnick, called the data "robust," and said they were looking to work with FDA to, "Identify the most efficient path toward commercialization."

No information was provided in Peregrine's press release or the www.ClinicalTrials.gov posting regarding the identity of the contractor or contractors.

Unnamed Contractor Blamed for Problems

Peregrine places blame on the as-yet-unnamed contractor or contractors, which it claims was responsible for the trial and subsequent data coding deficiencies.

"Due to the double-blind nature of the trial, Peregrine was not permitted to have access to either patient group assignments or related product coding information," it said. "As part of the trial's execution, Peregrine contracted with independent third-party contractors to execute treatment group assignments and oversee clinical trial material coding and distribution according to established procedures. A subsequent review of information has determined that the source of these discrepancies appear to have been associated with the independent third-party contracted to code and distribute investigational drug product."

Peregrine's stock has since plunged more than 80% after the release of the company's statement, reports Reuters.

Most Viewed News Articles

Lingering for more than two years, the revamped 21st Century Cures bill, unveiled in late November, has now been approved by the House and Senate and President Barack Obama has said he will sign it.View More

At the end of Thursday's Forbes healthcare summit in New York, some of the pharmaceutical and biotech industries’ top executives – from Pfizer, Regeneron, Eli Lilly, Gilead and Astellas – sat down and were presented with a simple question: Why don’t people like you? View More

After nearly 25 years of service at the US Food and Drug Administration (FDA), John Jenkins, M.D., Director of the Office of New Drugs (OND), will retire from the federal government on 6 January 2017. View More